Trial Profile

Rituximab + standard CHOP [cyclophosphamide, doxorubicin, vincristine and prednisone] (R S-CHOP) vs rituximab + bi-weekly CHOP (R Bi-CHOP) RCT [randomised controlled trial] (phase II/III) for stage III/IV low-grade B-cell lymphoma (LowBNHL-RS/BiCHOP-P2/3) (JCOG0203).

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cyclophosphamide; Doxorubicin; Granulocyte colony-stimulating factors; Prednisone; Rituximab; Vincristine
Indications B-cell lymphoma; Follicular lymphoma
Focus Therapeutic Use

22 Sep 2016 Biomarkers information updated
02 Jul 2013 Planned end date changed from 1 Feb 2010 to 1 Feb 2022 University Hospital Medical Information Network - Japan record.
19 Sep 2011 Results published in the Journal of Clinical Oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com